Literature DB >> 21443034

Ferritin and prolactin levels in multiple sclerosis.

Rafael Da Costa1, Martine Szyper-Kravitz, Zoltan Szekanecz, Tünde Csépány, Katalin Dankó, Yinon Shapira, Gisele Zandman-Goddard, Hedi Orbach, Nancy Agmon-Levin, Yehuda Shoenfeld.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is a common demyelnating disorder of the central nervous system (CNS) and ethiopathogenesis has yet to be fully elucidated. The disease may present in several clinical forms that are closely associated with disease morbidity. In recent years various environmental and hormonal factors have been implicated in the pathogenesis of autoimmunity.
OBJECTIVES: To evaluate ferritin and prolactin levels in MS patients and their correlation with clinical manifestations of the disease.
METHODS: Serum samples from 150 multiple sclerosis patients were evaluated for demographic characteristics, clinical parameters as well as prolactin and ferritin levels utilizing the Liaison chemiluminescent immunoassays (DiaSorin, Italy). Sera from 100 matched healthy donors were used as controls.
RESULTS: Hyperprolactinemia was documented in 10 of 150 MS patients (6.7%) and hyperferritinemia in 12 (8%), both of which were significantly more common in this group compared with healthy controls (P < 0.01 and P = 0.02 respectively). Among female MS patients, elevated prolactin levels were related to the secondary-progressive type of disease (P = 0.05), whereas hyperferritinemia was associated with male gender (P = 0.03) and with the relapsing-progressive type of the disease (P = 0.02). An inverse association was found between hyperferritinemia and the relapsing-remitting type of MS in male patients (P = 0.05)
CONCLUSIONS: Our results suggest a plausible association between these biomarkers and certain clinical types and gender among MS patients. Further studies combining clinical data, CNS imaging and these markers are warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21443034

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  11 in total

1.  Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients.

Authors:  Hedi Orbach; Gisele Zandman-Goddard; Mona Boaz; Nancy Agmon-Levin; Howard Amital; Zoltan Szekanecz; Gabriella Szucs; Josef Rovensky; Emese Kiss; Andrea Doria; Anna Ghirardello; Jesus Gomez-Arbesu; Ljudmila Stojanovich; Francesca Ingegnoli; Pier Luigi Meroni; Blaz' Rozman; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

2.  Prolactin is Not Associated with Disability and Clinical Forms in Patients with Multiple Sclerosis.

Authors:  Wildéa Lice de Carvalho Jennings Pereira; Tamires Flauzino; Daniela Frizon Alfieri; Sayonara Rangel Oliveira; Ana Paula Kallaur; Andrea Name Colado Simão; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Neuromolecular Med       Date:  2019-08-31       Impact factor: 3.843

Review 3.  Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease.

Authors:  Maire E Percy; Theo P A Kruck; Aileen I Pogue; Walter J Lukiw
Journal:  J Inorg Biochem       Date:  2011-08-19       Impact factor: 4.155

Review 4.  Ameliorating Role Exerted by Al-Hijamah in Autoimmune Diseases: Effect on Serum Autoantibodies and Inflammatory Mediators.

Authors:  Hussam Baghdadi; Nada Abdel-Aziz; Nagwa Sayed Ahmed; Hany Salah Mahmoud; Ayman Barghash; Abdullah Nasrat; Manal Mohamed Helmy Nabo; Salah Mohamed El Sayed
Journal:  Int J Health Sci (Qassim)       Date:  2015-04

5.  Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas.

Authors:  V Larouche; J A Correa; P Cassidy; C Beauregard; N Garfield; J Rivera
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107

6.  Inflammation associated anemia and ferritin as disease markers in SLE.

Authors:  Kamala Vanarsa; Yujin Ye; Jie Han; Chun Xie; Chandra Mohan; Tianfu Wu
Journal:  Arthritis Res Ther       Date:  2012-08-07       Impact factor: 5.156

7.  Ferritin in adult-onset still's disease: just a useful innocent bystander?

Authors:  Bella Mehta; Petros Efthimiou
Journal:  Int J Inflam       Date:  2012-03-25

8.  Increased levels of prolactin receptor expression correlate with the early onset of lupus symptoms and increased numbers of transitional-1 B cells after prolactin treatment.

Authors:  Yadira Ledesma-Soto; Francisco Blanco-Favela; Ezequiel M Fuentes-Pananá; Emiliano Tesoro-Cruz; Rafael Hernández-González; Lourdes Arriaga-Pizano; María V Legorreta-Haquet; Eduardo Montoya-Diaz; Luis Chávez-Sánchez; María E Castro-Mussot; Adriana K Chávez-Rueda
Journal:  BMC Immunol       Date:  2012-03-09       Impact factor: 3.615

Review 9.  COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.

Authors:  Carlo Perricone; Elena Bartoloni; Roberto Bursi; Giacomo Cafaro; Giacomo Maria Guidelli; Yehuda Shoenfeld; Roberto Gerli
Journal:  Immunol Res       Date:  2020-08       Impact factor: 2.829

Review 10.  The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome.

Authors:  Cristina Rosário; Gisele Zandman-Goddard; Esther G Meyron-Holtz; David P D'Cruz; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-08-22       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.